Search Results

You are looking at 21 - 30 of 299 items for :

Clear All
Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades and Kenneth Anderson

Peripheral neuropathy (PN) and asthenia (fatigue) are among the most commonly seen complications in patients undergoing multiple myeloma (MM) therapy. These potentially debilitating adverse effects are frequently dose limiting, and they may

Full access

Shaji K. Kumar

Treatment Options for Myeloma Now Categorized The predominant change to the NCCN Guidelines for Multiple Myeloma (MM) is the grouping of treatment regimens according to “preferred,” “other,” and “useful in certain circumstances,” according to

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller and Rashmi Kumar

be able to: Integrate into professional practice the updates to the NCCN Guidelines for Multiple Myeloma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Multiple Myeloma Disclosure of Relevant Financial

Full access

Stephanie J. Lee

. Treatment of multiple myeloma . Blood 2004 ; 103 : 20 – 32 . 3 Hayashi T Hideshima T Anderson KC . Novel therapies for multiple myeloma . Br J Haematol 2003 ; 120 : 10 – 17 . 4 Maloney DG Molina AJ Sahebi F . Allografting with

Full access

Noopur S. Raje, Andrew J. Yee and G. David Roodman

The past 2 decades have seen remarkable advances in the treatment of multiple myeloma (MM). These advances began with the use of high-dose melphalan and autologous stem cell transplant 1 followed by the introduction of immunomodulatory drugs

Full access

Sagar Lonial and Jesus F. San Miguel

The treatment approaches, goals of therapy, and underlying philosophy for how to approach the treatment of a patient with newly diagnosed myeloma have dramatically shifted over the past 20 years. This shift has occurred partly as a consequence of

Full access

Kenneth C. Anderson

Over the past decade, the treatment of multiple myeloma has been revolutionized by new drug approvals. Specifically, during the past 12 years, 16 treatments have been approved, including 7 new treatments in 2015 alone. “These advances have

Full access

Matthew Mei and George Somlo

Over the past decades significant therapeutic advances have been made in the treatment of multiple myeloma (MM). A population-based study of 45,595 patients showed substantial incremental increases in myeloma-specific survival in patients younger

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

. References 1 Attal M Harousseau JL Stoppa AM . A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma . N Engl J Med 1996 ; 335 : 91 – 97 . 2 Child JA Morgan GJ Davies FE . High

Full access

Ang Li, Qian Wu, Suhong Luo, Greg S. Warnick, Neil A. Zakai, Edward N. Libby, Brian F. Gage, David A. Garcia, Gary H. Lyman and Kristen M. Sanfilippo

Background Multiple myeloma (MM) is associated with a high risk of venous thromboembolism (VTE), especially when using treatment regimens containing immunomodulatory drugs (IMiDs; eg, lenalidomide or thalidomide). 1 Initial trials of IMiDs without